Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Decline in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 93,141 shares, a decrease of 64.1% from the July 15th total of 259,720 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 88,009 shares, the short-interest ratio is currently 1.1 days.

Indaptus Therapeutics Stock Performance

Indaptus Therapeutics stock traded up $0.02 during trading hours on Friday, reaching $1.08. 29,705 shares of the company’s stock traded hands, compared to its average volume of 451,192. The firm’s 50 day moving average is $2.57 and its 200-day moving average is $2.22. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $8.57. The firm has a market capitalization of $122.19 million, a price-to-earnings ratio of -0.07 and a beta of 1.18.

Indaptus Therapeutics (NASDAQ:INDP) last issued its earnings results on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($1.57) by $1.55.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on INDP. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.